Discovery Labs Suffers Another Setback for Surfaxin

Drug Industry Daily
A A
The FDA issued a complete response letter for Discovery Laboratories’ investigational synthetic surfactant drug Surfaxin, marking the fourth time the agency has decided not to approve the product.

To View This Article:

Login

Subscribe To Drug Industry Daily